GLASS分级在首次下肢血运重建中的验证
单中心回顾性研究纳入2005至2014年1060例患者的1180例首次开放或腔内下肢血运重建手术,按血管造影分为GLASS 1至3期。GLASS 2期和3期较1期与更高的1年和5年再干预、截肢和/或再狭窄复合结局风险相关,差异主要由再干预和再狭窄驱动而非大截肢;各期开放旁路远期结局均优于腔内介入。
要点
- GLASS 2期和3期较1期与更高的1年和5年RAS风险相关
- RAS差异主要由再干预和再狭窄驱动,而非大截肢
- 各GLASS分期下开放旁路的5年RAS率均低于腔内介入
核心结论
- 对首次下肢血运重建患者,GLASS可用于预测再干预和再狭窄。
- 各GLASS分期下开放旁路的长期结局均优于腔内介入。
研究设计与样本
- 单中心回顾性研究,纳入2005至2014年1060例连续患者的1180例首次开放或腔内下肢血运重建手术。
- 对1180例手术(91%)的血管造影图像进行GLASS 1、2、3期分级。
- 其中开放旁路552例(47%),腔内介入628例(53%)。
主要发现
- 1年RAS率:GLASS 1期33%、2期48%、3期53%。
- 5年RAS率:GLASS 1期45%(参照),2期65%(HR 1.7,95%CI 1.3-2.2,P<.001),3期69%(HR 2.3,95%CI 1.7-2.9,P<.001)。
- 5年死亡率与1期相比:2期45%(HR 1.1,95%CI 0.8-1.4,P=.69),3期49%(HR 1.2,95%CI 1.0-1.6,P=.11)。
- 腔内介入未能通过靶病变的比例随GLASS分期升高:1期4.5%、2期6.3%、3期13.3%(P<.01)。
关键数值与推荐
- 与开放旁路相比,腔内介入的5年RAS率更高:GLASS 1期49% vs 34%(HR 1.9,95%CI 1.1-3.5,P=.03)。
- GLASS 2期腔内介入5年RAS率69% vs 开放旁路52%(HR 1.7,95%CI 1.2-2.5,P<.01)。
- GLASS 3期腔内介入5年RAS率83% vs 开放旁路61%(HR 1.5,95%CI 1.2-2.0,P<.01)。
临床怎么用
- 可依据GLASS分级对首次下肢血运重建患者进行再干预和再狭窄风险分层。
- 在讨论血运重建方式时,可将各GLASS分期下开放旁路5年RAS率低于腔内介入的结果纳入决策参考。
局限性
- 单中心回顾性研究,可能存在选择偏倚。
- 仅91%的手术可获得影像用于GLASS分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Global Limb Anatomic Staging System (GLASS) was developed as a new anatomic classification scheme to grade the severity of chronic limb threatening ischemia. We evaluated the ability of this anatomic grading system to determine major adverse limb events after lower extremity revascularization. METHODS: We performed a single-institutional retrospective review of 1060 consecutive patients who had undergone 1180 first-time open or endovascular revascularization procedures for chronic limb threatening ischemia from 2005 to 2014. Using the review of angiographic images, the limbs were classified as GLASS stage 1, 2, or 3. The primary composite outcome was reintervention, major amputation (below- or above-the-knee amputation), and/or restenosis (>3.5× step-up by duplex criteria) events (RAS). The secondary outcomes included all-cause mortality, failure to cross the lesion by endovascular methods, and a comparison between bypass vs endovascular intervention. Kaplan-Meier estimates were used to determine the event rates at 1 and 5 years, and Cox regression analysis was used to adjust for baseline differences among the GLASS stages. RESULTS: Of all patients undergoing first-time revascularization, imaging studies were available for 1180 procedures (91%) for GLASS grading. Of these procedures, 552 were open bypass (47%) and 628 were endovascular intervention (53%). Compared with GLASS stage 1 disease (n = 267, 23%), stage 2 (n = 367; 31%) and stage 3 (n = 546; 42%) disease were associated with a greater risk of RAS at 1 year (stage 1, 33% vs stage 2, 48% vs stage 3, 53%) and 5 years (stage 1, 45% [reference]; stage 2, 65%; hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.3-2.2; P < .001; stage 3, 69%; HR, 2.3; 95% CI, 1.7-2.9; P < .001). These differences were mainly driven by reintervention and restenosis rather than by major amputation. The 5-year mortality was similar for stage 2 and 3 compared with stage 1 disease (stage 1, 40% [reference]; stage 2, 45%; HR, 1.1; 95% CI, 0.8-1.4; P = .69; stage 3, 49%; HR, 1.2; 95% CI, 1.0-1.6; P = .11). For all attempted endovascular interventions, failure to cross a target lesion increased with advancing GLASS stage (stage 1, 4.5% vs stage 2, 6.3% vs stage 3, 13.3%; P < .01). Compared with open bypass (n = 552; 46.8%), endovascular intervention (n = 628; 53.3%) was associated with a higher rate of 5-year RAS for GLASS stage 1 (49% vs 34%; HR, 1.9; 95% CI, [1.1-3.5; P = .03), stage 2 (69% vs 52%; HR, 1.7; 95% CI, 1.2-2.5; P < .01), and stage 3 (83% vs 61%; HR, 1.5; 95% CI, 1.2-2.0; P < .01) disease. CONCLUSIONS: For patients undergoing first-time lower extremity revascularization, the GLASS can be used to predict for reintervention and restenosis. Bypass resulted in better long-term outcomes compared with endovascular intervention for all GLASS stages.
引用
- Liang P, Marcaccio CL, Darling JD, et al. Validation of the Global Limb Anatomic Staging System in first-time lower extremity revascularization. J Vasc Surg. 2020. PMID: 33091516. doi:10.1016/j.jvs.2020.08.151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。